<DOC>
	<DOCNO>NCT02847728</DOCNO>
	<brief_summary>This observational , multicenter study patient treat nivolumab approve indication melanoma lung cancer Australia , EU , Switzerland , United States ( US ) . Targeted country EU study participation include Austria , Belgium , France , Germany , Italy , Spain , United Kingdom ( UK ) . Study objectives assess safety experience , survival , adverse event management , outcomes adverse event associate nivolumab routine oncology care facility .</brief_summary>
	<brief_title>Pattern Use Safety/Effectiveness Nivolumab Routine Oncology Practice</brief_title>
	<detailed_description>This observational , multicenter study patient treat nivolumab approve indication melanoma lung cancer Australia , EU , Switzerland , United States ( US ) . Targeted country EU study participation include Austria , Belgium , France , Germany , Italy , Spain , United Kingdom ( UK ) . Study objectives assess safety experience , survival , adverse event management , outcomes adverse event associate nivolumab routine oncology care facility . The study start 2016 , data collection continue March 2024 .</detailed_description>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Age â‰¥18 Histologically cytologically confirm diagnosis melanoma ( include uveal melanoma ) lung cancer Treatment commercial nivolumab first time , alone combination ipilimumab , approve indication nivolumab within 14 day inform consent study OR case treatment yet initiate , documentation treatment strategy determine informed consent study participation , treatment initiate within 28 day inform consent Prior participation clinical trial within past 4 week Previously treat antiPD1 , antiPDL1 , antiPDL2 antibody Previously treat antiCTLA4 lung cancer Current pending participation clinical trial Current pending systemic treatment cancer melanoma lung cancer Inability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>